Disease index

tetanus, diphtheria, pertussis

Vaccines · 2006–2017

3decisions
3medicines
1carried consumer input
0individual submissions

Every decision

MedicineMeetingOutcomeConsumer input
pertussis vaccine-acellular combined with diphtheria and tetanus toxoids (adsorbed) Maternal vaccination in the third trimester of each pregnancy, primarily to reduce the risk of pertussis in newborn infants up to 2 months of age. Mar 2017 Recommended with restriction input received
Pertussis vaccine acellular with Diphtheria and Tetanus Toxoids, adsorbed, injection Active immunisation against tetanus, diphtheria and pertussis in adolescents aged 10 to 18 years as a booster following primary immunisation. Mar 2006 Recommended no section in document
pertussis vaccine acellular with diphtheria and tetanus toxoids, adsorbed Active immunisation against tetanus, diphtheria and pertussis in persons aged 10 years and over as a booster following primary immunisation. Mar 2006 Recommended with restriction no section in document

What the PBS pays

$15M in government benefit over 2024–25, across 115,455 services.

This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.

MedicineGovernment benefit
Pertussis vaccine acellular with Diphtheria and Tetanus Toxoids, adsorbed $5M
diphtheria and tetanus toxoids combined with pertussis vaccine-acellular $5M
pertussis vaccine acellular with diphtheria and tetanus toxoids, adsorbed $5M

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.